Terms ending in 2029
Every in-force patent on AstraZeneca AB's record whose computed term ends in 2029, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,988,459 | ANTI-IFNAR1 Antibodies with Reduced FC Ligand Affinity In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 10,301,390 | ANTI-IFNAR1 Antibodies with Reduced FC Ligand Affinity In force · Medium confidence | AstraZeneca AB | In force | Medium confidence | |
| US 11,813,246 | Pharmaceutical Composition In force · Medium confidence | Alexion Pharma International Operations Limited | In force | Medium confidence | |
| US 12,220,403 | Pharmaceutical Composition In force · Low confidence | Alexion Pharma International Operations Limited | In force | Low confidence | |
| US 12,318,367 | Pharmaceutical Composition In force · Low confidence | Alexion Pharma International Operations Limited | In force | Low confidence | |
| US 12,364,684 | Pharmaceutical Composition In force · Low confidence | Alexion Pharma International Operations Limited | In force | Low confidence | |
| US 8,616,196 | Inhalation Device and a Method for Assembling Said Inhalation Device In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 7,425,637 | N3 Alkylated Benzimidazole Derivatives as Mek Inhibitors In force · High confidence | Alexion Pharma International Operations Limited | In force | High confidence | |
| US 7,960,395 | 5,7-Disubstituted Thiazolo[4,5-d]pyrimidines for the Selective Inhibition of Chemokine Receptors In force · High confidence | Kancera AB | In force | High confidence | |
| US 7,842,803 | Nicotinic Acetylcholine Receptor Ligands 101 In force · High confidence | Acturum Life AB | In force | High confidence | |
| 15 more term ends in 2029 · Pro | |||||
10 of 25 patents shown. Soonest term end first, then patent number.
Pro members see all 25.
11 of these are in force and held by AstraZeneca AB.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.